KOL Event on Tenax’s TNX-201 (imatinib): A Potential Treatment for Pulmonary Arterial Hypertension
|DATE:||June 2, 2022|
|TIME:||11:00 AM EDT|
About The Event
The webinar will feature presentations from Key Opinion Leaders (KOL’s) Anna Hemnes, MD (Vanderbilt University Medical Center), John Ryan, MD, MB, BCH, BAO (University of Utah), Bradley Maron, MD (Harvard Medical School), and Robert Frantz, MD, FACC (Mayo Clinic College of Medicine)
The discussion will focus on the current treatment landscape and unmet medical need in treating patients with pulmonary arterial hypertension (PAH) and on Tenax’s TNX-201, oral enteric coated imatinib, as a potential treatment solution. Results from the Phase 3 IMPRES study which evaluated GLEEVEC® (imatinib mesylate) for the treatment of PAH will also be discussed.
A live question and answer session will follow the formal presentations.